HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on CARISMA Therapeutics (NASDAQ:CARM) and maintained an $11 price target.
September 06, 2023 | 10:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CARISMA Therapeutics' stock may see positive movement due to the reiterated 'Buy' rating and maintained price target by HC Wainwright & Co.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in CARISMA Therapeutics, which could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100